New funding will help advance two one-time CRISPR treatments for inherited cardiovascular risks toward human trials.
Think about finding out that your risk of heart disease was largely written into your DNA long before you were born. Now imagine addressing that risk not with a lifetime of pills, injections or restrictive diets, but with a treatment designed to be given once. The idea still belongs more to the future than the present, yet it is becoming the direction of travel for modern medicine – and investors, regulators and researchers are beginning to take notice.
This week, Scribe Therapeutics announced that it has been awarded more than $25 million by the California Institute for Regenerative Medicine (CIRM) to advance two gene-editing programs targeting inherited drivers of cardiovascular and metabolic disease. The funding will help move the therapies closer to clinical trials, marking an important milestone for a company betting that some of the world’s most common chronic diseases may eventually be treated at their genetic roots [1].
Cardiovascular medicine has largely focused on managing risk once it becomes visible. High cholesterol? Lower it. High triglycerides? Control them. Heart attack? Prevent the next one. These approaches have undoubtedly saved millions of lives, but they often require lifelong adherence, and they frequently begin after years (or even decades) of silent damage inside the arteries. That reality is helping fuel a new generation of biotech companies focused on prevention rather than reaction.
Scribe’s latest funding supports two experimental therapies: STX-1200 and STX-1400. Both use CRISPR-based gene editing, a technology often described as molecular scissors because of its ability to make precise changes to genetic code.
While CRISPR has become synonymous with rare genetic diseases, Scribe is applying it to a much larger opportunity: common cardiometabolic conditions that collectively affect millions of people.
The hidden risk affecting one in five people
One of the company’s lead programs targets lipoprotein(a), commonly abbreviated as Lp(a). Researchers increasingly view it as one of the most important inherited risk factors for cardiovascular disease. Around one in five people worldwide have elevated Lp(a) levels; those individuals face a significantly higher risk of premature heart attacks and certain heart valve conditions.
What makes Lp(a) particularly challenging is that it is largely inherited. Unlike many cardiovascular risk factors, it is not something that can typically be solved through exercise, weight loss or dietary changes alone. In simple terms, if LDL cholesterol is often influenced by how we live, Lp(a) is more like a biological inheritance that follows us throughout life.
Scribe’s STX-1200 program is designed to directly target the gene responsible for producing Lp(a), with the goal of delivering a long-lasting reduction after a single treatment.
“We are proud to share that two of Scribe’s CRISPR-based genetic medicine approaches have been recognized by CIRM for their strong therapeutic potential to address cardiovascular disease for millions of patients,” said Dr Benjamin Oakes, co-founder and CEO of Scribe.
A second target with few good options
The company’s second funded program, STX-1400, focuses on triglycerides – fat-like particles that circulate in the bloodstream. Most people associate elevated triglycerides with cardiovascular risk, but in severe cases, they can also trigger acute pancreatitis, a painful and potentially life-threatening condition that often requires hospitalization.
For patients with inherited disorders such as familial chylomicronemia syndrome, treatment options remain limited and burdensome. Many must follow highly restrictive diets while still living with the constant threat of serious complications.
STX-1400 aims to target a gene called APOC3, which acts as a key regulator of triglyceride levels. Rather than repeatedly lowering triglycerides through ongoing treatment, the goal is to make a durable genetic adjustment that helps keep levels under control long-term.
The subtle distinction represents a fundamentally different philosophy of medicine: changing the underlying instructions rather than repeatedly correcting the consequences.
Longevity investors are paying attention
From a longevity perspective, the significance of this announcement extends beyond the size of the funding award. Cardiovascular disease remains the leading cause of death worldwide. Even among people who live longer than previous generations, heart disease continues to account for a substantial portion of lost healthspan, that’s why cardiovascular prevention is becoming one of the most active frontiers in longevity science.
The most compelling longevity technologies are the ones that quietly reduce risk across decades. Lowering the chances of a heart attack at 50, 60 or 70 may ultimately have a greater population-level impact than many of the more futuristic concepts that dominate headlines.
This is also where genetic medicine is beginning to evolve. The conversation is shifting toward tackling common diseases that place the greatest burden on healthcare systems and aging populations.
“CIRM’s preclinical development program is intended to move potential therapies toward clinical trials for patients who have no other options,” said Dr Lisa McGinley, Senior Science Officer for Preclinical Development at CIRM. “Genetic medicines such as those being developed by Scribe could be life-changing for the millions of people in California and the world who have genetic predisposition to forms of heart disease.”
Of course, these therapies remain in development, and many scientific, clinical and regulatory hurdles still lie ahead. Funding is not the same as approval, and promising biology does not always translate into successful medicines. However, the trend is difficult to ignore.
For generations, medicine has largely worked by continuously managing disease after it emerges. A growing number of biotechnology companies are now asking a different question: what if we could intervene much earlier, before years of damage accumulate? Scribe’s latest funding round represents another step toward that possibility.
And so we return to the idea that opened this story: the promise of a one-time treatment. Not because a single injection is inherently remarkable, but because of what it represents. A future where medicine is measured less by how effectively it manages chronic disease and more by how successfully it prevents it from taking hold in the first place. For longevity, that may be one of the most important shifts of all.
